MoneyWorks4Me

NATCO Pharma informs about disclosure

23 Apr 2024 Evaluate
Further to its earlier intimation dated November 2, 2023 about the successful completion of United States Food and Drug Administration’s (USFDA) inspection of the firm’s compliance to Pharmacovigilance requirements with zero observations, NATCO Pharma has informed that the Company is in receipt of the Establishment Inspection Report (EIR) from USFDA concluding the inspection as Closed.

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..